Lobe Sciences (TSE:LOBE)
:LOBE
Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.06
-C$0.01(-33.33%)
At close: 4:00 PM EST
C$0.06
-C$0.01(-33.33%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.18
Previous CloseN/A
Volume8.00K
Average Volume (3M)19.65K
Market Cap
C$28.41M
Enterprise ValueC$19.53M
Total Cash (Recent Filing)C$4.96M
Total Debt (Recent Filing)C$316.49K
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding284,102,500
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Psychedelic R&DLobe’s specialization in psychedelic-derived therapeutics targets a multi-year structural growth area in mental-health and neurology. A clear R&D focus concentrates scientific expertise and IP potential, positioning the company to benefit from secular demand and regulatory progress as treatments mature.
Modest Current LeverageLow reported debt relative to equity reduces near-term solvency pressure and gives management flexibility to fund clinical programs or access capital without immediate distress. Modest leverage is a durable structural strength versus highly leveraged peers in early-stage biotech.
Evidence Of Positive Gross Margins HistoricallyPrior periods with meaningful gross profit indicate the company’s activities can generate positive unit economics when commercialized. This suggests margins could support sustainable profitability if R&D yields scalable, revenue-generating therapies, reducing long-term business model risk.
Bears Say
No Recent RevenueTrailing-twelve-months revenue is zero while operating and net losses are sizable, meaning the company is not yet commercial. Persistent absence of revenue forces dependency on trial outcomes and external capital, limiting internal cash generation and elongating path to profitability.
Sustained Cash BurnDeeply negative operating and free cash flows indicate ongoing cash burn tied to R&D and operations. This creates recurring financing needs, shortens runway without fundraising, and raises dilution or program cut risks, constraining the company’s ability to advance multiple long-duration trials concurrently.
Unstable / Negative Equity HistoryHistorical episodes of negative equity reflect accumulated losses and an unstable capital base. Negative or highly variable equity levels can restrict access to favorable financing, increase cost of capital, and signal structural solvency vulnerability that hampers long-term investment and strategic optionality.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.03 and its highest was C$0.18 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$28.41M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 55 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.636%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---